Voyager Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Voyager Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2014 to 2023.
  • Voyager Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $4.04M, a 51.3% increase year-over-year.
  • Voyager Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $13.5M, a 38.6% increase year-over-year.
  • Voyager Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $11.2M, a 19.4% increase from 2022.
  • Voyager Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $9.34M, a 17.5% decline from 2021.
  • Voyager Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $11.3M, a 24.2% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $11.2M +$1.81M +19.4% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 $9.34M -$1.98M -17.5% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 $11.3M -$3.61M -24.2% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 $14.9M -$706K -4.51% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-07
2019 $15.6M -$70K -0.45% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-08
2018 $15.7M +$6.47M +70.1% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 $9.24M +$2.93M +46.4% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-03
2016 $6.31M +$2.28M +56.7% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-26
2015 $4.03M +$3.6M +848% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-14
2014 $425K Jan 1, 2014 Dec 31, 2014 10-K 2017-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.